NOVO Nordisk A S
Forward trial catalysts linked to NVO
CSA tracks 7 forward catalysts for NOVO Nordisk A S across 1 asset, spanning Phase 3. The nearest is a readout expected Mar 1, 2027 (day precision). Confidence across its tracked catalysts breaks down as 7 medium. Tracked indications include Obesity, Cardiovascular Disease, Overweight, and 1 more.
NVO in the full snapshot
The free sample on this page is a slice. In the current full CSA snapshot, NOVO Nordisk A S has:
Forward catalysts by year
Every catalyst in the snapshot comes with its date, date confidence and source link.
11 trials behind these assets
| Asset | Trial | Phase | Status | Primary completion | Role | Lead sponsor | Condition(s) |
|---|---|---|---|---|---|---|---|
| cagrilintide | NCT05567796 | Phase 3 | Active, not recruiting | 2024-10-30 | Experimental | Novo Nordisk A/S | Obesity |
| cagrilintide | NCT07011667 catalyst | Phase 3 | Active, not recruiting | 2027-03-01 | Experimental | Novo Nordisk A/S | Obesity |
| cagrilintide | NCT07220642 catalyst | Phase 3 | Active, not recruiting | 2027-05-11 | Experimental | Novo Nordisk A/S | Obesity; Overweight |
| cagrilintide | NCT07220759 catalyst | Phase 3 | Active, not recruiting | 2027-05-12 | Experimental | Novo Nordisk A/S | Overweight; Obesity; Type 2 Diabetes |
| cagrilintide | NCT07745504 catalyst | Phase 3 | Recruiting | 2027-05-18 | Experimental | Novo Nordisk A/S | Overweight; Obesity |
| cagrilintide | NCT07817251 catalyst | Phase 3 | Recruiting | 2027-06-09 | Experimental | Novo Nordisk A/S | Diabetes Mellitus, Type 2 |
| cagrilintide | NCT05669755 catalyst | Phase 3 | Active, not recruiting | 2027-09-01 | Experimental | Novo Nordisk A/S | Cardiovascular Disease |
| cagrilintide | NCT07564414 catalyst | Phase 3 | Recruiting | 2028-02-23 | Experimental | Novo Nordisk A/S | Obesity; Type 2 Diabetes |
| cagrilintide | NCT06780449 | Phase 3 | Active, not recruiting | 2028-08-28 | Experimental | Novo Nordisk A/S | Obesity |
| cagrilintide | NCT07282613 | Phase 3 | Recruiting | 2029-09-07 | Experimental | Novo Nordisk A/S | Diabetes Mellitus, Type 2 |
| cagrilintide | NCT07253285 | Phase 3 | Recruiting | 2030-03-20 | Experimental | Novo Nordisk A/S | Overweight; Obesity |
Every trial the CSA sample links to NVO's tracked assets.
Conditions studied
Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.
This sponsor's catalysts are a slice of the free CSA sample. The full snapshot covers active, industry-sponsored Phase 3 trials in cardiometabolic, oncology and immunology. Every forward catalyst carries its date, confidence grade and source link, and is linked to its sponsor's ticker when the sponsor is a listed company.
Get the full dataset — $499 →